A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels

Inclusion Criteria: * Male and female adult patients, body weight between 40-150 kg aged 18-65 years (inclusive) * Patients diagnosed with asthma with Forced Expiratory Volume (FEV1) ≥65% of the predicted normal value for the patient * Positive skin prick test to a specific allergen * Patients had to demonstrate a Provocative Dose 20% FEV1 decline (PD20) response to an aeroallergen in the graded allergen bronchoprovocation testing (ABP) at screening Exclusion Criteria: * Current active smokers * Patients who have been hospitalized or had emergency treatment for an asthma attack in the 12 months prior to study start * History of bleeding disorders * History of drug allergy * Pregnant women or nursing mothers * Females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception (surgical contraception or double barrier methods (to be continued for at least two months following last dose) are acceptable). * Sexually active males who have not been sterilized and are not using a condom * History of immunocompromise, including a positive HIV * A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. * History of drug or alcohol abuse within 12 months of study start Other protocol-defined inclusion/exclusion criteria may apply